ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - January 2020

Decade

Year

Issue

May 2022, Vol 3, No. 5

JAMA Forum

The Future of Medicare Advantage

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221684. doi:10.1001/jamahealthforum.2022.1684

The Costs of Long COVID

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221809. doi:10.1001/jamahealthforum.2022.1809

The Uncertain Future of Policies to Promote Access and Affordability Put in Place During the COVID-19 Pandemic

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221980. doi:10.1001/jamahealthforum.2022.1980

The Challenging Future of Long-term Care for Older Adults

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e222133. doi:10.1001/jamahealthforum.2022.2133
Viewpoint

Harnessing COVID-19 Data Through Collaboration—The Consortium of HCA Healthcare and Academia for Research Generation

Abstract Full Text
open access has audio
JAMA Health Forum. 2022;3(5):e220874. doi:10.1001/jamahealthforum.2022.0874

This Viewpoint describes the framework of a large COVID-19 research consortium that includes private, public-sector, and academic collaborating institutions.

Amplifying Appeals to the Common Good in COVID-19 Vaccine Messaging

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e220991. doi:10.1001/jamahealthforum.2022.0991

This Viewpoint highlights how appeals to self-interest as a means to encourage vaccination have come to prevail in the pandemic, and suggests a transition from this approach to appeals that reclaim a spirit of solidarity.

Prognostic Modeling and Major Dataset Shifts During the COVID-19 Pandemic: What Have We Learned for the Next Pandemic?

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221103. doi:10.1001/jamahealthforum.2022.1103

This Viewpoint examines prognostic modeling during the COVID-19 pandemic and discusses the chaos created by the major dataset shifts that challenged all efforts.

An Integrated Framework for Achieving National Health Goals

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221109. doi:10.1001/jamahealthforum.2022.1109

This Viewpoint proposes a practical framework for accomplishing national health goals that health systems and clinicians can adopt and policy makers can fund.

Original Investigation

Evaluation of Federal Policy Changes to the Hospice Benefit and Use of Hospice for Persons With ADRD

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e220900. doi:10.1001/jamahealthforum.2022.0900

This cross-sectional study examines the association of hospice use among patients with Alzheimer disease and related dementias with the passage of the US IMPACT Act and implementation of the 2-tier payment system.

Concordance of Hospital Ranks and Category Ratings Using the Current Technical Specification of US Hospital Star Ratings and Reasonable Alternative Specifications

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221006. doi:10.1001/jamahealthforum.2022.1006

This cross-sectional study aims to identify the changes in hospital ratings and rankings associated with alternative methodological choices in the calculation of the 2021 Centers for Medicare & Medicaid Services Hospital Compare star ratings.

COVID-19 and Hospital Financial Viability in the US

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221018. doi:10.1001/jamahealthforum.2022.1018

This cross-sectional study examines changes in the operational financial performance and overall financial viability of US hospitals during the COVID-19 pandemic.

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221096. doi:10.1001/jamahealthforum.2022.1096

This cross-sectional study examines whether new formulations of brand-name novel drugs were associated with novel drugs’ sales and/or therapeutic value as well as characterizes new formulations’ approval timing relative to the novel drug’s generic approval.

Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221116. doi:10.1001/jamahealthforum.2022.1116

This decision analytical model of prostate cancer screening programs in the Bahamas evaluates the projected benefit of limited screening programs and the implied resources required for their sustainable implementation.

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017

Abstract Full Text
open access has audio
JAMA Health Forum. 2022;3(5):e221158. doi:10.1001/jamahealthforum.2022.1158

This cross-sectional study evaluates spending by the Centers for Medicare & Medicaid on drugs granted FDA accelerated approval before and after confirmation of benefit from 2012 to 2017 with follow-up through 2020.

Association of Registered Nurse Staffing With Mortality Risk of Medicare Beneficiaries Hospitalized With Sepsis

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221173. doi:10.1001/jamahealthforum.2022.1173

This cross-sectional study examines the association of registered nurse workload with mortality in Medicare beneficiaries admitted to an acute care hospital with sepsis.

Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221229. doi:10.1001/jamahealthforum.2022.1229

This cross-sectional study assesses whether cancer mortality rates in 2020 were lower in countries with higher cancer-related spending and estimates across countries the incremental cost per averted cancer death.

Research Letter

Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e220888. doi:10.1001/jamahealthforum.2022.0888

This economic evaluation examines the magnitude and trend of prescription drug rebates in commercial markets from 2015 to 2019 and identifies insurance plan factors associated with rebates.

Trends in Real Estate Investment Trust Ownership of US Health Care Properties

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221012. doi:10.1001/jamahealthforum.2022.1012

This cross-sectional study examines the prevalence and characteristics of real estate investment trust–owned health care properties in the US health care sector.

Trends in Medical Debt During the COVID-19 Pandemic

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221031. doi:10.1001/jamahealthforum.2022.1031

This cross-sectional study evaluates the association between the COVID-19 pandemic and reported new medical debt from 2018 to 2021 across the US.

Out-of-Pocket Costs and Prescription Filling Behavior of Commercially Insured Individuals With Chronic Obstructive Pulmonary Disease

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221167. doi:10.1001/jamahealthforum.2022.1167

This cohort study uses a longitudinal access and adjudication data set to evaluate prescription out-of-pocket costs and filling behaviors of commercially insured individuals with chronic obstructive pulmonary disease (COPD).

In the News

FDA Outlines Proposed Ban on Menthol Cigarettes, Flavored Cigars

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221664. doi:10.1001/jamahealthforum.2022.1664

Federal Investigators Find Medicare Advantage Plans Too Often Deny, Delay Needed Care

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221781. doi:10.1001/jamahealthforum.2022.1781

Firearm-Related Deaths Surged During COVID-19 Pandemic’s First Year

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221936. doi:10.1001/jamahealthforum.2022.1936

After Mandate, COVID-19 Vaccinations Increased Among Nursing Home Staff

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e222069. doi:10.1001/jamahealthforum.2022.2069

Nearly 1 Billion People Globally Who Need Assistive Technologies Lack Access

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e222169. doi:10.1001/jamahealthforum.2022.2169
Correction

Error in Funding/Support

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221390. doi:10.1001/jamahealthforum.2022.1390

Error in Figure 1

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e221616. doi:10.1001/jamahealthforum.2022.1616
JAMA Health Forum Masthead

JAMA Health Forum

Abstract Full Text
open access
JAMA Health Forum. 2022;3(5):e220713. doi:10.1001/jamahealthforum.2022.0713
×